In a 66-year-old woman with familial interstitial lung disease and pulmonary hypertension, how will a right-heart catheterization change her management?

Right Heart Catheterization in ILD-PH: Critical for Accurate Diagnosis and Treatment Decisions

In a 66-year-old woman with familial ILD and suspected pulmonary hypertension, right heart catheterization (RHC) is essential because it will definitively confirm or exclude PH, accurately classify the hemodynamic phenotype, determine severity, and fundamentally alter treatment decisions—particularly regarding eligibility for pulmonary vasodilator therapy, lung transplantation evaluation, and prognostication.

Why RHC Changes Management in This Patient

Diagnostic Confirmation and Classification

RHC is the gold standard for diagnosing PH and is specifically recommended in ILD patients to confirm the diagnosis and support treatment decisions 1, 2. In your patient with familial ILD, this is particularly critical because:

• Echocardiography is unreliable in ILD: Studies show that echo misclassifies 40% of ILD patients as "low probability" for PH when RHC subsequently confirms its presence 3. Even with the ESC/ERS recommended tricuspid regurgitation velocity thresholds, echo has poor negative predictive value in ILD populations.

• PH prevalence is extremely high in symptomatic ILD: Among ILD patients with intermediate-to-high echo probability of PH (like your patient), RHC confirms PH in 85% of cases 4. In severe ILD requiring transplant evaluation, PH prevalence reaches 27-71% 5.

Hemodynamic Phenotyping Determines Treatment

RHC will distinguish between precapillary and postcapillary PH, which fundamentally changes management 1, 2:

• Pulmonary artery wedge pressure (PAWP) measurement is critical to exclude left heart disease as the primary driver (Group 2 PH), which would contraindicate pulmonary vasodilator therapy
• Pulmonary vascular resistance (PVR) quantification identifies severe PH (PVR >5 Wood units), present in 31% of ILD-PH patients 6, which may warrant consideration of targeted PH therapies in clinical trials or off-label use
• Accurate hemodynamic assessment prevents potentially harmful treatment with pulmonary vasodilators in patients with occult left heart disease 1

Transplant Evaluation

RHC is mandatory if lung transplantation is being considered 2. The guideline explicitly states: "RHC is recommended in patients with PH due to left heart disease (group 2) or lung disease (group 3) if organ transplantation is considered" (Class I recommendation). In your 66-year-old patient with familial ILD:

• Hemodynamic severity directly impacts transplant candidacy and urgency listing
• Severe PH (mean PAP >35 mmHg or PVR >5 WU) may require combined heart-lung transplant consideration
• Baseline hemodynamics guide perioperative risk stratification

Prognostic Stratification

RHC provides powerful prognostic information that changes monitoring intensity and treatment urgency 4:

• ILD-PH patients have 5-year survival of only 35% compared to 100% in ILD without PH
• Specific hemodynamic parameters predict mortality: venous oxygen saturation <65%, pulmonary artery compliance <2.2 mL/mmHg
• This information justifies more aggressive management and closer follow-up

Practical Approach to RHC in This Patient

Pre-RHC Assessment

Ensure the patient has:

• Optimized volume status: Diuretics adjusted to euvolemia to avoid falsely elevated PAWP
• Recent pulmonary function tests: DLCO <50% predicted and FVC/DLCO ratio elevation suggest higher PH likelihood 7
• 6-minute walk test: Distance <360m and post-exercise desaturation predict confirmed PH 4, 7

RHC Performance

The procedure must be performed at an expert center 1, 2 with attention to:

• Accurate PAWP measurement: Errors in PAWP assessment lead to misclassification and potentially harmful treatment decisions 1
• Complete hemodynamic profile: Mean PAP, PAWP, cardiac output, PVR, and mixed venous oxygen saturation
• Consideration of exercise hemodynamics: May unmask PH in borderline cases, though not yet standard practice

Post-RHC Management Decisions

If RHC confirms precapillary PH (mean PAP ≥20 mmHg, PAWP ≤15 mmHg, PVR >2 WU):

• Initiate transplant evaluation if appropriate candidate
• Consider enrollment in clinical trials for ILD-PH therapies
• Optimize oxygen therapy and pulmonary rehabilitation
• Avoid empiric pulmonary vasodilators outside clinical trials (insufficient evidence, potential harm)

If RHC shows severe PH (PVR >5 WU):

• Expedite transplant evaluation
• Consider multidisciplinary PH-ILD team consultation 8, 9
• More aggressive symptom management

If RHC excludes PH or shows mild elevation:

• Focus management on underlying ILD
• Repeat RHC if clinical deterioration occurs
• Avoid unnecessary PH-directed therapies

Critical Pitfalls to Avoid

• Do not rely on echocardiography alone: 40% false-negative rate in ILD populations 3
• Do not perform RHC at non-expert centers: Technical errors in PAWP measurement lead to misclassification 1
• Do not start pulmonary vasodilators empirically: Without RHC confirmation of precapillary PH, you risk treating occult left heart disease with potentially harmful drugs 2
• Do not delay RHC in symptomatic patients: The heterogeneous hemodynamic landscape of ILD-PH requires lower thresholds for invasive assessment 6

In summary, RHC in this patient will provide definitive diagnostic confirmation, accurate hemodynamic classification, prognostic information, and guide critical decisions regarding transplant evaluation and treatment eligibility—none of which can be reliably determined by noninvasive testing alone 1, 2, 4.